(HealthDay)—For patients with type 2 diabetes, direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) is associated with improved glycemic control and reduced antidiabetic medication use, according to a study ...
Jul 7, 2017
0
1
Globally, an estimated 71 million people are living with chronic hepatitis C virus (HCV). Over decades of infection, chronic HCV infection results in progressive damage to the liver and an increased risk for end stage liver ...
Jun 8, 2017
0
20
Use of the generic versions of directly-acting antiviral (DAA) drugs that are available in India to treat hepatitis C virus (HCV) infection is not only cost effective but actually saves lifetime costs for treating infected ...
May 17, 2017
0
0
The number of hepatitis C virus (HCV) cases reported in reproductive-aged women in the United States has increased substantially in recent years. Thus, more children are being born to HCV-infected mothers than at any time ...
May 8, 2017
0
1
An international study led by researchers at Monash University' Biomedicine Discovery Institute (BDI) has shone light on the way the Hepatitis C Virus (HCV) hijacks the communication systems in the host cells it infects, ...
May 8, 2017
0
39
The use of heroin and other illicit drugs has been shown to trigger a response from the body's immune system. Consequently, high levels of immune activation (inflammation)—that is associated with the progression of chronic ...
Apr 13, 2017
0
0
A big data study of hepatitis C and more than 500 patients with the virus has opened the way for a better understanding of how the virus interacts with its human hosts.
Apr 11, 2017
0
69
FDA-approved oral direct-acting antiviral (DAA) regimens produce high sustained virologic response (SVR) rates for all six hepatitis C virus (HCV) genotypes and for patient populations historically considered difficult to ...
Mar 20, 2017
0
0
(HealthDay)—For patients with hepatitis C virus (HCV) infection and biopsy-proven cirrhosis, sustained viral response (SVR) is associated with a reduction in critical events, both liver and non-liver related, according ...
Jan 4, 2017
0
0
A US jury has ordered pharmaceutical giant Gilead Sciences to pay $2.5 billion to competitor Merck in a patent infringement case involving a drug used to treat hepatitis C, the two companies said.
Dec 16, 2016
0
0
